The CVR dividend is a non-cash event with no immediate financial impact, but the sale process for biosimilar assets could unlock value. Monitor for updates on asset sales and any restrictions from the Loan Agreement. The CVRs expire in two years, so the timeline for monetization is uncertain.
Price Chart
Executive Summary
Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining biosimilar assets, completing its transformation into a pure-play immuno-oncology company. The CVRs entitle holders to a pro rata share of net proceeds from the sale of patents, IP, royalties, and cell lines, but payments are uncertain and subject to a 2026 loan agreement. The CVRs expire on October 7, 2028, with no guaranteed payout, making this a speculative unlock of non-core asset value.
Key Facts
- Coherus declared a special dividend of CVRs to stockholders of record as of September 30, 2026, with a distribution date of October 7, 2026.
- CVRs entitle holders to net cash proceeds from the sale of Legacy BioSim Assets, including patents, IP, royalties, cell lines, and related materials.
- The CVRs are non-transferable, will not be listed on any exchange, and expire on October 7, 2028, with no payment if no proceeds are received.
- The company has retained an investment bank to assist in the sale process and is subject to restrictions under a Loan Agreement with Innovatus Life Sciences Lending Fund I, L.P., dated August 12, 2026.
- Coherus is transforming into a fully integrated innovative oncology company focused on LOQTORZI (toripalimab-tpzi) and pipeline candidates casdozokitug and tagmokitug.
Financial Impact
No specific dollar amounts disclosed for the CVR proceeds; value depends on future sale of biosimilar assets, which are not quantified.
Risk Factors
- No guarantee of any payment under the CVRs if assets are not sold or monetized before expiration.
- The Loan Agreement with Innovatus Life Sciences may restrict or delay the sale of Legacy BioSim Assets and CVR payments.
- CVRs are non-transferable and have no public trading market, limiting liquidity for holders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3346515 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Press Release | $1.34 $1.29 | ▼ −4.10% | ▼ −3.11% | $1.16 (−13.43%) |
Jul 22, 2026 10w ago | Press Release | $1.43 $1.33 | ▼ −6.99% | ▼ −9.89% | $1.16 (−18.88%) |
Jun 15, 2026 15w ago | 8-K | $1.38 $1.45 | ▲ +5.07% | ▲ +4.87% | $1.16 (−15.94%) |
Jun 12, 2026 16w ago | Institutional Cluster | $1.40 $1.54 | ▼ −10.00% | ▼ −8.22% | $1.16 (+17.14%) |
May 28, 2026 18w ago | DEFA14A | $1.65 $1.50 | ▼ −9.09% | ▼ −5.95% | $1.16 (−29.70%) |
May 11, 2026 20w ago | Press Release | $1.71 $1.36 | ▼ −20.47% | ▼ −18.74% | $1.16 (−32.16%) |
May 5, 2026 21w ago | DEFA14A | $1.75 $1.47 | ▼ −16.00% | ▼ −18.78% | $1.16 (−33.71%) |
May 4, 2026 21w ago | Press Release | $1.73 $1.57 | ▼ −9.25% | ▼ −14.89% | $1.16 (−32.95%) |
Mar 9, 2026 29w ago | Press Release | $1.95 $1.70 | ▼ −12.82% | ▼ −12.67% | $1.16 (−40.51%) |
Mar 2, 2026 30w ago | Press Release | $1.65 $1.60 | ▼ −3.03% | ▲ +4.91% | $1.16 (−29.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access